Orchid Pharma Limited (NSE:ORCHPHARMA)
India · Delayed Price · Currency is INR 983.45
-13.55 (-1.36%)
Oct 1, 2026, 3:30 PM IST
Orchid Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 8,523 | 12,328 | 13,976 | 8,194 | 6,659 | 5,596 | |
Revenue Growth | 0.22% | -11.79% | 70.57% | 23.05% | 19.00% | 24.33% |
Cost of Revenue | 5,468 | 8,774 | 9,247 | 5,032 | 4,013 | 3,271 |
Gross Profit | 3,055 | 3,554 | 4,729 | 3,162 | 2,646 | 2,325 |
Selling, General & Admin | 918.09 | 1,208 | 1,121 | 729.83 | 663.66 | 648.58 |
Other Operating Expenses | 1,529 | 1,563 | 1,968 | 1,323 | 1,145 | 1,145 |
Operating Expenses | 2,806 | 3,513 | 3,647 | 2,386 | 2,357 | 2,664 |
Operating Income | 249.04 | 40.59 | 1,082 | 776.25 | 289.93 | -338.9 |
Interest Expense | -132.04 | -89.84 | -127.88 | -163.55 | -322.26 | -320.12 |
Interest & Investment Income | - | 89.42 | 205.58 | 163.48 | 6.18 | 4.19 |
Earnings From Equity Investments | -12.14 | -138.73 | -16.61 | -28.98 | -21.54 | -35.23 |
Currency Exchange Gain (Loss) | - | 150 | 88.65 | 67.35 | 52.01 | 75.82 |
Other Non Operating Income (Expenses) | 254.32 | 40.29 | 25.54 | 77.8 | 126.6 | 4.9 |
EBT Excluding Unusual Items | 359.18 | 91.72 | 1,258 | 892.36 | 130.93 | -609.34 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.15 | 5.12 |
Gain (Loss) on Sale of Assets | - | 79.28 | -3.33 | -1.88 | 7.75 | 0 |
Other Unusual Items | -65.74 | -73.33 | - | - | 392.1 | - |
Pretax Income | 293.44 | 97.68 | 1,254 | 890.47 | 530.93 | -604.21 |
Income Tax Expense | -1.19 | -1.92 | -96.45 | -31.19 | - | - |
Earnings From Continuing Operations | 294.64 | 99.59 | 1,351 | 921.67 | 530.93 | -604.21 |
Earnings From Discontinued Operations | - | - | - | - | -67.75 | 584.7 |
Net Income | 294.64 | 99.59 | 1,351 | 921.67 | 463.18 | -19.51 |
Net Income to Common | 294.64 | 99.59 | 1,351 | 921.67 | 463.18 | -19.51 |
Net Income Growth | -65.42% | -92.63% | 46.55% | 98.98% | - | - |
Shares Outstanding (Basic) | 51 | 60 | 60 | 48 | 41 | 41 |
Shares Outstanding (Diluted) | 51 | 60 | 60 | 48 | 41 | 41 |
Shares Change | -0.08% | - | 23.82% | 18.49% | - | - |
EPS (Basic) | 5.81 | 1.66 | 22.55 | 19.06 | 11.35 | -0.48 |
EPS (Diluted) | 5.81 | 1.66 | 22.55 | 19.06 | 11.35 | -0.48 |
EPS Growth | -65.40% | -92.64% | 18.33% | 67.93% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -2,640 | -1,022 | 611.77 | -665.75 | 780.71 |
Free Cash Flow Per Share | - | -44.08 | -17.07 | 12.65 | -16.31 | 19.13 |
Gross Margin | 35.85% | 28.83% | 33.84% | 38.59% | 39.74% | 41.55% |
Operating Margin | 2.92% | 0.33% | 7.74% | 9.47% | 4.35% | -6.06% |
Profit Margin | 3.46% | 0.81% | 9.66% | 11.25% | 6.96% | -0.35% |
Free Cash Flow Margin | - | -21.41% | -7.31% | 7.47% | -10.00% | 13.95% |
EBITDA | 607.09 | 463.89 | 1,497 | 1,094 | 837.72 | 531.03 |
EBITDA Margin | 7.12% | 3.76% | 10.71% | 13.35% | 12.58% | 9.49% |
D&A For EBITDA | 358.05 | 423.3 | 415.15 | 317.72 | 547.79 | 869.93 |
EBIT | 249.04 | 40.59 | 1,082 | 776.25 | 289.93 | -338.9 |
EBIT Margin | 2.92% | 0.33% | 7.74% | 9.47% | 4.35% | -6.06% |
Revenue as Reported | 8,777 | 12,692 | 14,296 | 8,502 | 6,853 | 5,686 |
Advertising Expenses | - | 0.92 | 0.35 | - | - | - |